GO
| HSI1 | 25,182.39 | 0.00 | -- |
| HSCEI1 | 8,425.82 | 0.00 | -- |
| Back Zoom + Zoom - Block Traded | |
|
2026-05-29 10:30:02 UBS published a research report stating that TIGERMED (03347.HK) management indicated that operating performance since the beginning of this year has been broadly in line with company guidance, namely achieving a double-digit YoY revenue growth target in 2026 and adjusted net profit of RMB600 million to RMB700 million. As of mid-May, new orders increased by more than 20% YoY, with a target of at least reaching the 2025 level. The company also emphasized that pricing for new orders is continuing to recover, rising 10% compared with 4Q25. Regarding artificial intelligence applications, TIGERMED has launched medical writing and translation tools, and is integrating AI with its GCP business, with real-world studies to be conducted in 2H26. Although the total investment scale may still change, the company highlighted a target of RMB200 million to RMB400 million. UBS said that due to pricing stickiness and the potential impact of AI, price recovery in the clinical CRO sector may be slower than expected. It therefore lowered its revenue and gross margin forecasts for 2026-2028, resulting in EPS cuts of 3.3%, 8.2% and 13.1%, respectively. The broker reduced its TP to 52 from 59.9 and maintained a Buy rating. (sl/da)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |